Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01897012
Title Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Burkitt lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

lymphoma

Hodgkin's lymphoma

Therapies

Romidepsin

Alisertib

Age Groups: adult
Covered Countries USA


No variant requirements are available.